Meri Muminovic, MD
Hematology-Oncology · Miramar, FLNPI 1942706916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 82 payments — averaging $78.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$989
- Tempus AI, Inc$568
- Coherus Oncology, Inc.$513
- E.r. Squibb & Sons, L.L.C.$474
- Jazz Pharmaceuticals Inc.$420
- Pfizer$410
- plus $3K from 21 others
What the payments were for
- Consulting fees$1302%
- Food & beverage$5,84590%
- Education$4858%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $989 |
| Tempus AI, Inc | 13 | $568 |
| Coherus Oncology, Inc. | 5 | $513 |
| E.r. Squibb & Sons, L.L.C. | 5 | $474 |
| Jazz Pharmaceuticals Inc. | 4 | $420 |
| Pfizer | 2 | $410 |
| Genentech USA, Inc. | 5 | $371 |
| Sanofi | 3 | $293 |
| Amgen | 3 | $270 |
| Astellas Pharma US Inc | 3 | $235 |
| Janssen Scientific Affairs, LLC | 3 | $222 |
| Incyte Corporation | 2 | $207 |
| Regeneron Healthcare Solutions, Inc. | 2 | $192 |
| Johnson & Johnson | 5 | $158 |
| Gilead | 1 | $148 |
| EMD Serono, Inc. | 1 | $125 |
| Springworks Therapeutics, Inc. | 1 | $123 |
| Blueprint Medicines Corporation | 1 | $122 |
| Rigel Pharmaceuticals, Inc. | 1 | $121 |
| Eisai Inc. | 1 | $108 |
| Lilly USA, LLC | 1 | $108 |
| Seagen Inc. | 1 | $85 |
| Sanofi-aventis U.S. LLC | 1 | $83 |
| Teleflex LLC | 1 | $34 |
| Array Biopharma Inc | 1 | $29 |
| Legend Biotech USA Inc. | 1 | $28 |
| Novartis | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Miramar
- Isaac LevyPembroke Pines$55K
- Amer RassamTallahassee$11K
- Roger FebresKissimmee$11K
- Steven WeissCoral Springs$6K
- Carlos BarburHialeah$5K
- Bruce StechmillerSt Augustine$0
- Seongseok YunTampa$0
- Peter MoussaTampa$0
- Andrew DeniccoMiami$0
- Robert KilleenHoliday$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.